Advertisements

Ambrosol Teva

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ambrosol Teva

Quick Facts

Property Description
Active ingredient Ambroxol hydrochloride
Form Tablet, oral solution, syrup
Pharmacological class Mucolytic and secretolytic agent
Common use Facilitating respiratory clearance
Origin Synthetic derivative

Ambrosol Teva: Classification and Chemical Origin

Ambrosol Teva is a pharmaceutical preparation defined by its active ingredient, Ambroxol, a substance categorized as a secretolytic and mucolytic agent. This medicine is a synthetic derivative that is chemically related to the alkaloid bromhexine. The therapeutically effective compound is typically administered as the salt, Ambroxol hydrochloride. Its primary purpose within its pharmacological class is to address conditions associated with thickened respiratory secretions. Ambroxol is characterized by its efficacy in thinning mucus and its established utility in airway management.


Composition, Active Substance, and Available Forms

The active substance responsible for the drug’s effects is Ambroxol hydrochloride, supplied in various dosage forms by the manufacturer, Teva Pharmaceutical Industries. The drug is available as a tablet for systemic delivery, and notably, as an oral solution or syrup using an aqueous vehicle, which often features flavoring agents to suit the target patient group. The prevalent route of administration for this single-active-ingredient product remains oral.


General Purpose: Facilitating Respiratory Clearance

The general purpose of using this medicine is to promote the mobilization and effective clearance of thick, viscous respiratory secretions. As a mucolytic and secretolytic agent, the substance thins the consistency of the phlegm while stimulating the production of thinner fluid. This combined effect contributes to the enhancement of mucociliary clearance, a process recognized for restoring the natural transport function of the respiratory tract. This aids the patient in clearing accumulated mucus, thereby relieving the sensation of congestion and supporting unobstructed breathing.

Regulatory References

  1. Ambroxol- and bromhexine-containing medicines - referral
Advertisements

What side effects are possible with Ambrosol Teva?

Possible Side Effects and Safety Information

Ambrosol Teva (ambroxol hydrochloride) is generally well-tolerated, with most adverse reactions being mild and involving the gastrointestinal system or localized sensory effects.

Adverse Reactions by Frequency

Frequency Category Examples of Adverse Reactions (System-Organ Class)
Common (up to 1 in 10) Nausea, taste disturbances (dysgeusia), decreased sensation (hypoesthesia) in the mouth and throat.
Uncommon (up to 1 in 100) Vomiting, diarrhea, abdominal pain, indigestion (dyspepsia), dry mouth, fever.
Rare (up to 1 in 1,000) Hypersensitivity reactions, rash, hives (urticaria), heartburn.
Not known (cannot be estimated) Severe allergic reactions, Severe Cutaneous Adverse Reactions (SCARs).

Serious and Clinically Significant Reactions

The most serious documented safety concerns are Severe Cutaneous Adverse Reactions (SCARs) and severe allergic responses, for which the frequency is classified as unknown but reports exist. These include:

  • Anaphylactic reactions (e.g., anaphylactic shock, angioedema).
  • SCARs such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), erythema multiforme, and acute generalized exanthematous pustulosis (AGEP).

Treatment must be discontinued immediately if any signs of a progressive skin rash or mucosal lesions appear.

Safety Restrictions and Precautions

  • Contraindications include known hypersensitivity to the active substance (ambroxol) or bromhexine, and use is not recommended in children under 2 years of age.
  • Pregnancy and Lactation: Use is not recommended during pregnancy, especially the first trimester, and should be avoided during breastfeeding as the substance passes into breast milk.
  • Use with Caution is required for patients with peptic or duodenal ulcers, and in those with serious hepatic (liver) or renal (kidney) impairment, where accumulation of metabolites may necessitate a dose reduction or longer dosing intervals.
  • Drug Interaction: Concomitant use with cough suppressants is not recommended due to the risk of accumulation of liquefied bronchial secretions and airway obstruction.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The following section details the officially documented manifestations and required emergency actions for an overdose of Ambroxol hydrochloride, as outlined in government regulatory information.

Overdose symptoms are officially stated to be consistent with an extension of known undesirable gastrointestinal effects observed at normal doses. These effects primarily include nausea, vomiting, diarrhea, abdominal pain, and heartburn. In cases of extreme overdosage, there is a theoretical potential for hypotension (low blood pressure), although no specific severe poisoning effects have been consistently recorded in human overdose reports.

Required Emergency Actions

The regulatory guidance mandates that individuals who have taken more than the recommended dosage consult a doctor or seek immediate medical assistance. The official treatment for an overdose is defined as symptomatic and supportive treatment, and the patient should be observed.

There is no specific antidote known for an Ambroxol overdose. Furthermore, regulatory documents note that overdose management must account for the accumulation of metabolites in patients with severe renal insufficiency.

When to Seek Immediate Medical Help

Urgent medical attention is required upon suspicion of an overdose or if any progressive or severe symptoms manifest. The medication must be discontinued immediately and medical consultation sought if signs of severe cutaneous adverse reactions (SCARs), such as a progressive skin rash, appear.

Advertisements

Therapeutic Uses of Ambrosol Teva

What Ambrosol Teva Treats: Main Uses and Benefits

Ambrosol Teva is generally considered relevant for easing symptoms related to specific respiratory conditions. The medicine provides support that helps ease the overall burden of symptoms, particularly when they interfere with normal daily life. The product is relevant in contexts involving heightened systemic burden due to certain distressing symptoms. This is commonly used across conditions presenting with episodic or fluctuating manifestations, such as acute or chronic bronchitis, where symptoms create noticeable physiological strain.


Ease Productive Cough and Phlegm

This medication is used in situations involving symptoms related to physical discomfort from a productive (wet) cough. It helps address symptom clusters where thick, sticky mucus and phlegm create noticeable interference with daily comfort. The key benefit may assist with providing supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.

“It helps manage the symptoms that often create noticeable interference with daily stability during respiratory episodes.”

Quick Fact: Supports general well-being during symptomatic phases


Support Chronic Respiratory Conditions

Ambrosol Teva is commonly used across conditions presenting with episodic or fluctuating symptom patterns, such as chronic obstructive pulmonary disease (COPD) or chronic bronchitis, where symptoms interfere with daily functioning. It is applied across domains where additional symptomatic support is needed during phases of increased distress or discomfort. This provides support that helps ease the overall symptom burden and assists with maintaining stability.

Regulatory References

  1. European Medicines Agency therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Ambrosol Teva (Ambroxol hydrochloride) eligibility is strictly defined by regulatory documents, excluding certain populations and requiring caution in others.

Contraindications and Non-Eligibility

Classification Population/Condition
Contraindicated Patients with known hypersensitivity to Ambroxol or related substances.
Contraindicated Children under 2 years of age.
Contraindicated Patients with rare hereditary problems like fructose intolerance (for syrup/liquid forms) or galactose intolerance (for tablet forms).

Restricted or Conditional Use

Use is restricted or requires caution in patients with a history of peptic or duodenal ulcers, and those with compromised airway motility.

Organ Impairment: Patients with severe renal impairment (kidney disease) or serious hepatic impairment (liver disease) should be administered the medicine with caution. Dose adjustments are necessary for these groups due to the expected accumulation of metabolites.

Pregnancy and Lactation Status: The medicine is not recommended during the first trimester of pregnancy or for nursing mothers (lactation), as the substance is excreted in breast milk. Use in the second and third trimesters is permitted only if the benefit is determined to outweigh the risk, following usual medical precautions.

Adults and children aged 2 years and older are generally eligible for use.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ambroxol hydrochloride is defined by specific pharmacodynamic conflicts, pharmacokinetic modifications, and population-dependent clearance considerations documented in government regulatory labeling.

Documented Drug-Drug Interactions

The most prominent documented restriction is a pharmacodynamic conflict with antitussives (cough suppressants). Regulatory agencies formally advise against co-administration because the suppression of the cough reflex, when combined with the medicine's action of thinning secretions, carries the risk of the accumulation of bronchial secretions and potential airway obstruction.

In contrast, a pharmacokinetic enhancement is documented when this medicine is co-administered with select antibiotics, including Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline. This interaction officially leads to an increase in the concentration of these antibiotics within the lung tissues and bronchial secretions.

Population-Specific Constraints

The official prescribing information highlights constraints related to specific patient conditions that alter the drug's exposure. For individuals with severe renal impairment, the accumulation of hepatic metabolites is expected. Similarly, in cases of severe hepatic impairment, a reduction in drug clearance is observed. These are documented disease-drug interactions that officially change the drug's pharmacokinetic profile. No mandatory separation rules for administration timing are specified, and official documentation reports no clinically relevant unfavorable interactions mediated by metabolic pathways (e.g., CYP enzymes).

Advertisements

Mechanism of Action

Modulation of Airway Secretion Viscosity

Ambroxol hydrochloride acts as a secretagogue by stimulating Type II Pneumocytes in the alveolar tissue to increase the synthesis and release of pulmonary surfactant. This molecular action physically alters the properties of respiratory secretions by reducing their surface tension and adhesiveness. This reduction in adherence forces directly contributes to the functional operation of the mucociliary clearance pathway and facilitates the mobilization and transport of fluid.


Blockade of Peripheral Sensory Nerve Signals

A separate, rapid mechanism involves a local anesthetic effect achieved by blocking specific voltage-gated sodium channels (Nav channels) found on the peripheral sensory nerve endings in the airway mucosa. This interaction suppresses the generation and transmission of irritant signals, which results in reduced sensory nerve excitability of the airway lining.


Modulation of Airway Tissue Integrity Pathways

The drug also functions as a modulator of the inflammatory microenvironment through its anti-inflammatory and antioxidant properties. This involves the inhibition of key pro-inflammatory mediator release and the scavenging of reactive oxygen species (ROS). This mechanism provides cytoprotection and maintains the functional integrity of the respiratory epithelium against damage caused by oxidative stress and inflammation.

Advertisements

Dosage and Administration Information

How to Use Ambrosol Teva

This section describes the administration principles and dosing regimens for Ambroxol hydrochloride (Ambrosol Teva).


Administration Guidelines

Instruction Category Guidelines
Route of Administration The route for the tablet, syrup, and solution formulations is oral (by mouth).
Timing in Relation to Meals The medicine is directed to be taken after a meal.
Liquid Intake The drug must be taken with an adequate amount of fluid (e.g., water) to support proper use.

Dosing and Duration

A phased dosing structure is typically used, beginning with a higher frequency for a short period before transitioning to a maintenance regimen.

Dosage Principle Regimen for Adults and Children Over 12 Years
Initial Course 30 mg administered three times daily (TID) for the first 2 to 3 days.
Continuation Reduced to 30 mg administered two times daily (BID).
Maximum Daily Intake The total daily dose should not exceed 120 mg.

The initial 30 mg TID frequency is followed by the BID frequency for the continuation of the course. Self-treatment with the product should not exceed 4 to 5 days without professional consultation. For patients with renal or hepatic impairment, caution is necessary, often requiring the use of lower doses or longer time intervals between administrations due to potential metabolite accumulation.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Ambrosol Teva

Evidence for Approved Use in Acute and Chronic Respiratory Conditions

Research has examined the use of Ambrosol Teva for conditions marked by functional limitations associated with abnormal mucus secretion and impaired mucus transport. The primary research designs used in research exploring how symptoms change over time have included short-term Randomized Controlled Trials (RCTs) and summaries of multiple studies (meta-analyses). These studies monitored outcomes related to physical discomfort, such as the thickness and volume of phlegm, along with patient-reported outcomes describing perceived discomfort associated with cough severity and difficulty in expectoration.

The findings describe patterns observed in the studies over these short intervals. Research highlights changes measured during the study period in how easily patients reported clearing their airways. This evidence contributes to the broader evidence landscape where data show patterns related to short-term changes in these symptoms.

Studies Comparing Ambrosol Teva to Placebo and Other Agents

Some research has been evaluated in comparative settings, where the drug was observed in trials alongside an inactive substance (a placebo) or against other existing treatments intended for similar conditions where symptoms may vary in intensity. The studies monitored the drug in settings where a placebo or other substance was also evaluated.

The results from these comparative trials describe patterns related to symptom evolution, but the reported outcomes varied across different studies. This research contributes to understanding symptom patterns by providing a frame of reference. It is important to remember that study results reflect the specific conditions under which they were conducted, and comparative evidence is lacking for some combinations of conditions and treatments.

Duration of Study and Long-Term Outcomes

Most research was studied for short-term symptom changes, such as the duration of an acute episode or a few weeks in chronic conditions. Long-term effects are not fully established and there is limited information for long-term outcomes regarding the sustained impact on functional measures, quality of life, or the potential for reducing future acute flare-ups in chronic diseases. The follow-up durations were limited in the most controlled trials.

What is Still Uncertain About Ambrosol Teva

While research has explored the drug's activity in several scenarios, certainty remains low in several key areas. The evidence quality varies across studies, leading to some inconsistency in reported findings. Furthermore, the evidence is limited for certain conditions. The available evidence highlights what is known — and what is still uncertain — and research provides context but not individual predictions.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ambrosol Teva (FAQ)


Q: Is Ambrosol Teva considered an antibiotic or an antiviral medicine?

Official regulatory documents classify the active substance, Ambroxol hydrochloride, as a mucolytic and secretolytic agent. This means its function is to thin mucus and aid in its removal from the airways, not to treat bacterial or viral infections.

Q: Are there any common over-the-counter pain relievers that interact with Ambrosol Teva?

Official drug labels specifically note a restriction against taking this medicine with cough suppressants (antitussives), as this combination can cause mucus accumulation. Regulatory data does not typically specify unfavorable interactions with common over-the-counter pain relievers.

Q: Are there specific food or drink items mentioned in official documents that should be avoided when taking Ambrosol Teva?

Official product information advises taking the medicine after a meal and with sufficient fluid. There is generally no evidence that food significantly affects how the medicine works, and specific dietary items are not usually listed as being restricted.

Q: Does Ambrosol Teva contain lactose, gluten, or other common allergens?

The full list of ingredients (excipients) in the product varies by form, but tablets often contain lactose, and liquid formulations may contain fructose or sorbitol. Regulatory documents state it is contraindicated (should not be used) in patients with known hereditary problems like galactose or fructose intolerance.

Q: What happens if I take more Ambrosol Teva than described in the package information?

If more than the labeled amount is taken, regulatory documents state that serious symptoms are not commonly reported. Symptoms that have been observed in short-term studies include restlessness and diarrhea. Treatment for taking too much is generally symptomatic and supportive.

Q: What are the conditions under which Ambrosol Teva is officially approved for use?

Official regulatory bodies have approved the medicine for the secretory therapy of both acute and chronic broncho-pulmonary diseases. This includes conditions where there is a disturbance of bronchial secretion and difficulty with mucus transport.

Q: Is Ambrosol Teva a brand name, and are there generic versions available?

Ambrosol Teva is a specific brand name containing the active substance Ambroxol hydrochloride. Ambroxol hydrochloride is a well-established generic ingredient, and several generic versions of the medicine may be available depending on the market.

Q: Does Ambrosol Teva cause drowsiness or affect my ability to drive?

Based on official post-marketing data and clinical studies, there is no clear evidence that the medication significantly affects the ability to drive or operate machinery. Dizziness is a possible, though rare, side effect that has been reported.

Q: How long after starting Ambrosol Teva should a person expect to notice its effect?

Official patient information states that the onset of action, where the effect on mucus begins, may occur within about 30 minutes after taking the oral dose. The full therapeutic effect will depend on the specific condition being addressed.

Q: What should I do if I accidentally miss a dose of Ambrosol Teva?

Patient information leaflets often describe an approach where, if a dose is missed, it can be taken when remembered, provided it is not too close to the next scheduled dose. Official guidelines state that a double dose should not be taken to make up for a missed one.

Q: Does using Ambrosol Teva make me more sensitive to sunlight?

Official lists of side effects do not typically include photosensitivity (increased sensitivity to sunlight) as a common or uncommon adverse reaction. If signs of a progressive skin rash or mucosal lesions appear, regulatory documents advise immediately discontinuing the treatment, as these may be signs of a serious skin reaction.

Q: Are there any warnings about using Ambrosol Teva if I have high blood pressure?

Official regulatory warnings for the single-ingredient Ambroxol product do not usually list high blood pressure (hypertension) as a specific precaution. Precautions are primarily directed toward those with ulcer history, kidney/liver impairment, and compromised airway motility.

Q: Can older adults use Ambrosol Teva, and are there special considerations for this age group?

The standard adult dosing regimen is generally applicable to older adults. Regulatory documents typically do not recommend a dose change based on age alone, unless the person has significant kidney or liver problems that affect how the drug is cleared from the body.

Q: Are there any known interactions between Ambrosol Teva and alcohol consumption?

For the tablet form of the medicine, a clinically significant interaction with alcohol is not usually reported in official labeling. However, certain liquid forms of the medicine may contain small amounts of ethanol (alcohol) or other excipients which may be relevant for some patients.

Q: Can people with respiratory conditions like asthma use Ambrosol Teva?

Regulatory sources describe that the medicine is administered with caution in patient populations with certain compromised respiratory conditions, including asthma. This caution is noted due to the potential risk of mucus accumulation causing airway obstruction.

Q: Does Ambrosol Teva have a risk of dependence or addiction?

Based on official safety data and pharmacological classification, there is no indication that the active substance, Ambroxol, has a potential for dependence or abuse.

Q: Does taking Ambrosol Teva make it harder to fall asleep?

Official regulatory listings for common and uncommon side effects do not typically list insomnia or difficulty sleeping. The reported nervous system side effects are generally limited to mild symptoms like taste disturbances.

Q: Are there any specific lifestyle changes that are mentioned alongside using Ambrosol Teva?

Administration instructions often emphasize the need to take the medicine with adequate liquid. Official regulatory guidance also often highlights the importance of consuming plenty of liquid throughout the day to support the medicine's intended action.

Q: Do official documents mention any effects of Ambrosol Teva on fertility?

Official documents state that clinical data on the drug's effect on human fertility is not available. However, preclinical animal studies conducted do not indicate direct or indirect harmful effects on fertility.

Q: Is it safe to crush or chew Ambrosol Teva tablets, according to regulatory information?

If the product is a prolonged-release capsule, the regulatory instructions will specifically state that the capsule must be swallowed whole and not chewed or crushed. For standard tablets, official information typically does not contain instructions for crushing or chewing, and the product is generally administered whole.

Q: Can I stop taking Ambrosol Teva suddenly, or should I finish the package as described?

As the medicine is intended for short-term relief of symptoms, patient information leaflets generally suggest that you may stop taking the medicine when your symptoms improve. You do not typically need to finish a fixed course if the symptoms are gone.

Q: Has Ambrosol Teva been studied in people with diabetes?

Official warnings highlight that liquid formulations may contain sugar substitutes such as sorbitol. This is noted in regulatory documents as a special consideration for patients with diabetes mellitus who must monitor their total intake of these substances.

Advertisements

How should Ambrosol Teva be stored and disposed of?

Storage and Disposal Requirements

The medicine's regulatory labeling defines mandatory conditions for storage, stability, and disposal to maintain product quality and safety.

Requirement Type Official Condition
Temperature Store at a temperature not exceeding 30 C.
Child Safety Keep this medicine out of the sight and reach of children.
Liquid Handling Do not freeze liquid formulations (oral solution/syrup).
In-Use Stability Use oral solution/syrup within 6 months of first opening.
Disposal Do not throw away any medicines via wastewater or household waste.

Storage must include protection from direct light exposure, and the product should be kept in its original packaging. For disposal, official instructions require the user to ask a pharmacist for guidance on authorized take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ambrosol Teva found in:

A-Z Index: